Kailera Targets Structure's '183 Patent in European Dispute, Escalating Section 1782 Discovery Case

Kailera Targets Structure's '183 Patent in European Dispute, Escalating Section 1782 Discovery Case

The legal and clinical battle in the once-daily oral GLP-1 receptor agonist market has escalated significantly between newly public Kailera Therapeutics, Inc. (NASDAQ: KLRA) and Structure Therapeutics Inc. (NASDAQ: GPCR).

On July 22, 2026, Kailera filed an ex parte application for Section 1782 discovery assistance in the U.S. District Court for the Northern District of California (Case No. 3:2026mc80216) against Structure and its wholly owned subsidiary, Gasherbrum Bio, Inc.

Compelling US Discovery for European Patent Fight

The dispute centers on Structure’s European patent, known as the '183 patent, which was assigned to Gasherbrum Bio. This patent covers critical chemical compounds that enable once-daily oral dosing for small-molecule GLP-1 receptor agonists, such as Structure's lead candidate aleniglipron (GSBR-1290). Kailera is actively challenging this patent before the European Patent Office (EPO).¹

Because the EPO lacks the authority to compel the disclosure of internal corporate documents, Kailera has turned to U.S. federal courts under 28 U.S.C. § 1782. If granted, the application would force Structure to hand over internal communications, research data, and documents for use in the European proceedings.

The case is currently proceeding before Magistrate Judge Thomas S. Hixson. In late July 2026, the court issued multiple orders admitting out-of-state counsel (pro hac vice) to represent both Kailera and Structure, signaling that both clinical-stage companies are preparing for a high-stakes legal battle over the intellectual property underlying their oral pipelines.

Clinical Pipelines and Financial Context

Both companies are clinical-stage biopharmaceutical firms with zero revenue but significant capital backing to fund their respective pipelines and ongoing litigation:

• Structure Therapeutics (GPCR): Carries a $3.38 billion market cap, holding $272.6 million in cash against $6.2 million in debt as of June 30, 2026. Structure is advancing aleniglipron into Phase 3 development (the ACCOMPLISH program) and is awaiting key Q4 2026 readouts from its Phase 2 Body Composition study and SWITCH trial (transitioning patients from injectable GLP-1s to oral aleniglipron).
• Kailera Therapeutics (KLRA): Holds a $2.10 billion market cap, with $130.3 million in cash against $10.2 million in debt as of June 30, 2026. Kailera's stock recently hit a 52-week low of $15.63 in late August 2026, but the company continues to attract major institutional support. Disclosures from Q2 2026 show that Atlas Venture acquired a 5.1 million share position (valued at $113.9 million) and Wellington Management acquired a 2.9 million share stake (representing a 2.25% holding).